• JHU-083: From Glutaminase to Neuro-Redox Assays

  2026-08-27

  JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor designed for selective glutaminase perturbation in cerebral CD11b cells. This article explains how to use it as a mechanistic tool for experimental cerebral malaria research and neuro-redox assay design while avoiding unsupported conclusions from hepatic toxicity studies.

• Dutasteride Assays: From DHT Biology to Causal Design

  2026-08-27

  Dutasteride is a dual 5-alpha-reductase inhibitor for dissecting testosterone-to-DHT signaling in prostate models. This guide introduces a causal, compartment-aware assay strategy inspired by recent hepatocyte–macrophage research without overstating cross-domain evidence.

• Cefazedone (Refosporen): Applied Lab Workflows

  2026-08-26

  Cefazedone (Refosporen) supports reproducible broth-dilution, susceptibility, time-kill, and translational PK/PD workflows spanning Gram-positive and Gram-negative bacterial infections. This practical guide connects solvent handling and MIC determination with the time-dependent exposure findings reported in community-acquired pneumonia.

• Capillarisenol C and ER Stress-Driven Autophagic Death

  2026-08-26

  The reference study identifies capillarisenol C, a bisphenol from Artemisia capillaris, as an inducer of ER stress-associated cytotoxic autophagy in HepG2 and Huh7 liver cancer cells. Its use of apoptosis inhibition, autophagy perturbation, ER stress markers, and 4-PBA rescue provides a useful framework for distinguishing autophagic cell death from nonspecific cytotoxicity.

• Targeting GDH in HSCs to Alleviate Liver Fibrosis

  2026-08-25

  The reference study identifies glutamine catabolism in hepatic stellate cells as a therapeutically relevant metabolic dependency in liver fibrosis. Its central innovation is linking reduced SIRT4 expression to increased GDH activity, α-ketoglutarate production, and HSC proliferation, while showing that both EGCG treatment and SIRT4 overexpression can restrain fibrotic progression.

• ML385 for Reproducible NRF2 Assays

  2026-08-25

  This scenario-based guide explains how ML385 (SKU B8300) can be incorporated into cell viability, cytotoxicity, oxidative-stress, and therapeutic-resistance experiments. It connects product specifications with practical controls for dosing, solvent management, interpretation, and vendor selection.

• Tunicamycin: N-Glycosylation Inhibitor for ER Stress

  2026-08-24

  Tunicamycin is a potent N-glycosylation inhibitor and an endoplasmic reticulum stress inducer used to dissect glycoprotein synthesis, UPR signaling, and inflammatory responses. Its strongest research value is mechanistic: it creates an upstream glycosylation blockade that can be measured through GRP78, ATF6, inflammatory mediators, viability, and pathway-specific controls.

• Batimastat (BB-94): Reliable Cell Assays

  2026-08-23

  This scenario-driven guide explains how Batimastat (BB-94), SKU A2577, can improve interpretation of cell viability, proliferation, cytotoxicity, and MMP-related experiments. It covers mechanism, solvent controls, storage, dose interpretation, tumor models, and practical vendor-selection criteria.

• GSK-923295 for Reproducible Mitotic Assays

  2026-08-22

  This scenario-driven guide explains how GSK-923295 (SKU A3450) can support mechanistic cell-cycle, viability, proliferation, and cytotoxicity studies through defined CENP-E inhibition. It covers formulation, assay compatibility, protocol optimization, data interpretation, and practical vendor-selection criteria for cancer research.

• PP 2 (AG 1879): From Src Biology to Translation

  2026-08-21

  PP 2 (AG 1879) offers a practical way to interrogate Src family kinase signaling across oncology, immunology, and vascular biology. This thought-leadership guide connects its biochemical selectivity with evidence from glioma, T-cell, and ROS-driven arterial models while defining the controls needed for translationally credible experiments.

• Ranolazine: From Ion Flux to Translational Strategy

  2026-08-20

  A mechanism-led perspective on using Ranolazine to connect late sodium current inhibition, myocardial relaxation, metabolic efficiency, and carefully bounded liver-cell research.

• Osteoblast ECM1 and Anti-Androgen Resistance

  2026-08-20

  The reference study identifies osteoblast-derived ECM1 as a microenvironmental driver of enzalutamide resistance in bone metastatic prostate cancer. It maps an ECM1–ENO1–GRB2/SOS1–MAPK axis and shows that blocking ECM1 or ENO1 can restore treatment sensitivity, providing a rationale for targeting tumor–bone interactions in bmCRPC.

• Antiarrhythmic Drugs and KCa2 Channels in AF

  2026-08-19

  The reference study systematically tested commonly used antiarrhythmic drugs against human KCa2.2 and KCa2.3 channels using automated whole-cell patch clamp. Its results show that dofetilide and propafenone inhibit these channels, whereas the observed potency is generally too low to explain their clinical antiarrhythmic effects, refining how KCa2 channels should be considered in atrial fibrillation treatment research.

• Streptavidin – Cy5 for Translational Oncology

  2026-08-19

  A thought-leadership guide connecting USP42–JNK/p38 apoptosis biology with strategic assay design using Streptavidin – Cy5 for tissue imaging, immunofluorescence, in situ hybridization, and flow cytometry.

• Dutasteride: Designing Mechanism-First Assays

  2026-08-18

  Dutasteride is a dual 5-alpha-reductase inhibitor suited to layered studies of DHT biology, prostate cancer research, and apoptosis. This article shows how an immunometabolic liver-injury study can sharpen assay design without overstating cross-domain evidence.

443 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page